# Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity

> **NCT04222920** · PHASE4 · COMPLETED · sponsor: **Reade Rheumatology Research Institute** · enrollment: 78 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **OTHER:** Dose reduction to 2mg/L
- **OTHER:** Dose reduction to 5mg/L
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT04222920
- **Lead sponsor:** Reade Rheumatology Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-01
- **Primary completion:** 2023-09-11
- **Final completion:** 2023-09-11
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04222920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04222920, "Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04222920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*